MEDIA RELEASE– VenstraMedical, a cardiovascular medical device company, today announced that it has received a strategic investment from Highcroft Capital, a Minnesota-based venture capital firm specializing in early-stage MedTech innovation. The investment will accelerate development of VenstraMedical’s next-generation percutaneous ventricular assist device (pVAD) — a low-profile, full-flow cardiac support system designed to provide complete ventricular unloading for critically ill cardiac patients.
VenstraMedical is pleased to share preclinical results of our pVAD system development at #TCT2025 presented by Dr. Suku Thambar, Chief Medical Officer, at "Innovation Session 10: Advances in Percutaneous Pump Updates" beginning at noon on Monday, October 27th at Exhibition Level | Hall E | Innovation Theater.
VenstraMedical is proud to be featured in the American Society for Artificial Organs (ASAIO) Journal highlighting the pre-clinical testing of our novel pVAD platform.
The Gold Coast Cardiology Conference-Innovations in Interventions will take place from 18-20th of September in the Gold Coast, Australia. Our cofounder, Dr. Suku Thambar, is a Co-Course Director of the conference. He and several of the VenstraMedical Medical Advisor Board members along with fellow cofounder and CEO, Martin Cook, will be participating in the conference. VenstraMedical is a proud sponsor of this conference!
Venstra Medical (#LSIEurope25 Presenter) has developed what it believes to be the world’s smallest and most powerful percutaneous ventricular assist device (pVAD) for treating cardiogenic shock.
VenstraMedical will be attending LSI Europe '25, Medtech's premier partnering event held this September in London-be sure to connect with our CEO, Martin Cook, if you are planning to attend!
There's no better validation of our development efforts at VenstraMedical than to get featured in Forbes Magazine! We are eager to get our technology to those who could benefit from our FULL hemodynamic support while being delivered in a small 9F platform.
VenstraMedical is proud to share the company recently secured a $1,000,000 grant award from MTPConnect’s Targeted Translation Research Accelerator (TTRA) Drugs and Devices program, an initiative of Australia's Medical Research Future Fund.
VenstraMedical is pleased to share our recent company milestone as we work towards developing a novel pVAD platform for patients suffering from Cardiogenic shock.
VenstraMedical is delighted to be participating in the Mayo Clinic Cardiology and Radiology Innovation Summit in May. We are very much looking forward to discussing our unique ‘Next-Generation’ temporary cardiac assist device, a percutaneous catheter pump (pVAD), with thought leaders, investors, and cardiologists. The forum will no doubt be an exciting opportunity and a unique opportunity to share ideas with the people who are shaping our industry.
When it comes to mechanical circulatory support devices like pVADs one must consider pressure when evaluating the flow performance. That’s why we are proud to publicly share our test results of our pump system using the established “HQ Curve.”
VenstraMedical is developing a next-generation technology providing temporary cardiac support to the most critically ill cardiac patients. Their percutaneous catheter pump (pVAD) is built on a novel, patented platform with seven granted patents. The device is designed for minimally invasive delivery, collapsing into a small 9F catheter before expanding in situ.
Congratulations to VenstraMedical Cofounder, Dr. Suku Thambar, on his poster presentation at #THT2025 highlighting the superior hydraulic performance of the VenstraMedical pVAD platform!